* Heart failure comparison patients without hyperkalemia matched on age, sex, and duration of heart failure on the hyperkalemia/index date † As present at the time of heart failure diagnosis. ‡ Manifest chronic kidney disease was defined on the date of the second of two measurements more than 90 days apart of a creatinine value corresponding to an eGFR below 60 mL/min/1.73m2, or on the first date of a hospital diagnosis of chronic kidney disease, see text and Supplementary material with codes
Abbreviations: ACEis, angiotensin-converting enzyme inhibitors; ARBs, angiotensin-receptor II blockers; CI, confidence interval; eGFR, estimated Glomerular Filtration Rate; NSAIDs, non-steroidal anti-inflammatory drugs.PR, prevalence ratio * Heart failure comparisons without HK individually matched to heart failure patients with HK on age, sex, and heart failure duration, see text. †Adjusted for age, sex, and heart failure duration by matched design, and, by Cox regression analyses, for heart failure treatment regimen, number of acute heart failure hospitalizations 6 months before the HK/index date, eGFR category, Charlson Comorbidity Index score, presence of diabetes/chronic kidney disease/ hypertension, use of ACEis/ARBs, spironolactone, or potassium supplements ‡The prior-event-rate-ratio adjusted hazard ratio is the ratio of the two age, sex, and heart failure duration matched rate ratios observed 6 months after vs. 6 months before the HK/index date,see text Table S5 . Chronic heart failure: Baseline characteristics among patients with first hospital diagnosed heart failure, stratified by eGFR category and subsequent incidence of hyperkalemia. * Patients categorized according to lowest measured eGFR before or on admission date with heart failure; presence of dialysis overrules any eGFR measurement result. † Conditions possibly underlying heart failure; hierarchical categorization: presence before/at first heart failure diagnosis of 1) cardiomyopathy (with or without any of the following diagnoses); 2) valvular heart disease (with or without any of the other diagnoses except cardiomyopathy); 3) myocardial infarction (with or without atrial fibrillation); 4) atrial fibrillation only; and 5) none of these diagnoses. ‡ Manifest chronic kidney disease was defined on the date of the second of two measurements more than 90 days apart of a creatinine value corresponding to an eGFR below 60 mL/min/1.73m2, or on the first date of a hospital diagnosis of chronic kidney disease. Abbreviations: ACEis, angiotensin-converting enzyme inhibitors; ARBs, angiotensin-receptor II blockers; CI, confidence interval; eGFR, estimated Glomerular Filtration Rate; HK, hyperkalemia; NSAIDs, non-steroidal anti-inflammatory drugs.
. * Heart failure comparison patients without hyperkalemia matched on age, sex, and duration of heart failure on the hyperkalemia/index date † As present at the time of heart failure diagnosis. ‡ Manifest CKD was defined on the date of the second of two measurements more than 90 days apart of a creatinine value corresponding to an eGFR below 60 mL/min/1.73m2, or on the first date of a hospital diagnosis of chronic kidney disease, see text and Supplementary material with codes
Abbreviations: ACEis, angiotensin-converting enzyme inhibitors; ARBs, angiotensin-receptor II blockers; CI, confidence interval; eGFR, estimated Glomerular Filtration Rate; NSAIDs, non-steroidal anti-inflammatory drugs; PR, prevalence ratio 76 (3.98-5.69 ) -* Heart failure comparisons without HK individually matched to heart failure patients with HK on age, sex, and heart failure duration, see text. †Adjusted for age, sex, and heart failure duration by matched design, and, by Cox regression analyses, for heart failure treatment regimen, number of acute heart failure hospitalizations 6 months before the HK/index date, eGFR category, Charlson Comorbidity Index score, presence of diabetes/chronic kidney disease/ hypertension, use of ACEis/ARBs, spironolactone, or potassium supplements ‡The prior-event-rate-ratio adjusted hazard ratio is the ratio of the two age, sex, and heart failure duration matched rate ratios observed 6 months after vs. 6 months before the HK/index date,see text * Heart failure comparisons without HK individually matched to heart failure patients with HK on age, sex, and heart failure duration, see text. †Adjusted for age, sex, and heart failure duration by matched design, and, by Cox regression analyses, for heart failure treatment regimen, number of acute heart failure hospitalizations 6 months before the HK/index date, eGFR category, Charlson Comorbidity Index score, presence of diabetes/chronic kidney disease/ hypertension, use of ACEis/ARBs, spironolactone, or potassium supplements ‡The prior-event-rate-ratio adjusted hazard ratio is the ratio of the two age, sex, and heart failure duration matched rate ratios observed 6 months after vs. 6 months before the HK/index date, see text * Patients categorized according to lowest measured eGFR before or on admission date with heart failure; presence of dialysis overrules any eGFR measurement result. † Conditions possibly underlying heart failure; hierarchical categorization: presence before/at first heart failure diagnosis of 1) cardiomyopathy (with or without any of the following diagnoses); 2) valvular heart disease (with or without any of the other diagnoses except cardiomyopathy); 3) myocardial infarction (with or without atrial fibrillation); 4) atrial fibrillation only; and 5) none of these diagnoses. ‡ Manifest chronic kidney disease was defined on the date of the second of two measurements more than 90 days apart of a creatinine value corresponding to an eGFR below 60 mL/min/1.73m2, or on the first date of a hospital diagnosis. Abbreviations: ACEis, angiotensin-converting enzyme inhibitors; ARBs, angiotensin-receptor II blockers; CI, confidence interval; eGFR, estimated Glomerular Filtration Rate; HK, Figure S1 . Required strength of an unmeasured confounder to explain our associations assuming that 50% of the heart failure population had hyperkalemia and that the prevalence of the unmeasured confounder was 25%.
*HR indicates hazard ratio for the association between hyperkalemia and the different outcomes. For example, to explain an adjusted HR of ~ 2.0 (brown line) for acute hospitalization associated with hyperkalemia, a confounder that is four times more frequent among hyperkalemia than nonhyperkalemia patients would need to increase the hazard of acute hospitalization by a factor of 10 or more to explain our findings fully, if no increased hazard actually existed.
